Engflag

Oftafilm

Quick links to important sections

Oftafilm

Oftafilm_EN

Method of action: Analgesic, Anti-Inflammatory, Corrective Metabolism Of Bone And Cartilaginous Tissue, Other Drugs For Disorders Of The Musculo-Skeletal System

Treatment option: Glaucoma, Cataract, Corneal Transplant, Surgery, Cataract Extraction

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oftafilm

Quick Facts

Property Description
Active Ingredient Sodium Hyaluronate (Hyaluronate)
Form Ophthalmic Viscoelastic Solution (Eye Drops)
Pharmacological Class Ocular Lubricant / Tear Substitute
Primary Action Sustained surface protection and lubrication
Manufacturer SAVAL (South America focus)

1. What Type of Ophthalmic Product is Oftafilm?

Oftafilm (often marketed as Oftafilm SP) is classified as a proprietary viscoelastic ophthalmic solution used to supplement and stabilize the natural tear film on the eye's surface. Developed by SAVAL, it contains the active ingredient Sodium Hyaluronate. It belongs to the pharmacological class of ocular lubricants and tear substitutes. Unlike non-viscoelastic solutions that wash away quickly, this formulation is designed to improve tear film stability.

The unique viscoelastic structure of Oftafilm is recognized for its ability to maintain a protective layer on the eye, which is beneficial for tissues like the cornea and conjunctiva. This extended contact time helps support the surface of the eye, which is especially helpful during activities that strain the eyes, such as prolonged screen time.

2. What is the Key Component of Oftafilm?

The primary functional ingredient in Oftafilm is the high-molecular-weight polymer, Sodium Hyaluronate, which provides the solution's core characteristics of surface adherence and viscosity. This substance is a derivative of Hyaluronic Acid, a naturally occurring biopolymer. Polymers of this class are characterized as being highly bio-compatible with the human eye.

The specific manufacturing process ensures the Hyaluronate is highly pure, resulting in a product that forms a clear, resilient film. This allows the solution to provide necessary lubrication without the cloudiness or heavy sensation often associated with thicker ointments or less advanced formulas.

3. What is Oftafilm’s General Purpose?

The general purpose of Oftafilm is to achieve sustained hydration and physical shielding of the ocular surface, thereby providing extended relief from common discomforts. It is typically used for the temporary relief of symptoms associated with eye irritation, such as a burning feeling or the sensation of a foreign body.

By creating a durable and stable film, Oftafilm minimizes the rapid evaporation of natural tears and reduces friction when blinking. This persistent lubrication is a key mechanism of action, supporting the overall health of the eye's surface and promoting the eye's ability to maintain comfort throughout the day.

Regulatory References

  1. ocular lubricants and tear substitutes (NIH, Viscoelastics)

What side effects are possible with Oftafilm?

Possible Side Effects and Safety Information

The official regulatory safety documentation for Oftafilm, an ophthalmic solution containing Sodium Hyaluronate, details a safety profile primarily associated with localized and transient adverse reactions. Safety information is organized according to the frequency and system-organ class, as is standard practice in regulatory labeling.

Frequency and Organ Systems

The most frequently observed adverse reactions are classified as Common in clinical data for related products. These effects are mainly localized to the site of administration.

Classification System-Organ Class Officially Documented Adverse Reactions
Common Eye Disorders Instillation site discomfort (stinging, burning), Ocular Pain, Conjunctival Hyperemia (eye redness), Transient Blurred Vision
Other Effects Nervous System Disorders Headache, Dysgeusia (taste disturbance)

Transient blurred vision typically occurs immediately after instillation and resolves rapidly, reflecting the exposure-related pattern documented in official sources.

Serious Adverse Reactions and Safety Restrictions

While the product is generally well-tolerated, the regulatory safety profile includes documentation of rare but potentially serious events. The most significant safety concern is the risk of Acute Hypersensitivity Reactions (severe allergic responses) following administration.

  • Contraindication: Oftafilm is explicitly contraindicated for use in any individual with a known hypersensitivity (allergy) to Sodium Hyaluronate or any other ingredient present in the formulation.
  • Population Note: Regulatory documents indicate that older adults have not shown overall differences in safety or effectiveness compared to other adult patients in studies of related ophthalmic preparations.

This information establishes the official boundaries and expectations for the medicine’s safety profile.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Oftafilm (Sodium Hyaluronate ophthalmic solution) is defined by its low systemic risk and topical route of administration.

Overdose scope Regulatory Statement
Systemic Toxicity Risk The risk of serious or life-threatening systemic toxicity is consistently classified as negligible in regulatory documents for this drug class.
Documented Manifestations No specific systemic signs or symptoms of overdose (e.g., CNS or cardiovascular effects) are formally documented in official labeling. Potential effects are typically limited to localized ocular irritation following excessive application.
Emergency Response Regulatory Statement
Immediate Help Required Urgent medical assistance is required if localized eye irritation persists or worsens following excessive use, or in the event of accidental oral exposure.
Supportive Management Management of potential overdose is restricted to symptomatic and supportive treatment. No specific antidote is known or required for this product.

Official prescribing information confirms that systemic overdose is not expected due to the substance's non-toxic profile and negligible absorption. Immediate action is mandated by regulators only for the persistence of localized adverse effects, not for anticipated severe systemic poisoning. Monitoring or specialized procedures beyond supportive care are generally not documented.

Therapeutic Uses of Oftafilm

What Oftafilm Treats: Main Uses and Benefits

Oftafilm is used in situations involving certain distressing symptoms related to the ocular surface, applying across domains where additional symptomatic support is needed. It is considered relevant for easing discomfort when the natural tear film is unstable or deficient. As an ocular lubricant, the product is primarily indicated for the temporary relief of burning and irritation due to dryness of the eye. It helps address symptom clusters that may become intense or disruptive, such as the sensations of a foreign body, grittiness, burning, and stinging.

The product is commonly used across conditions characterized by periods of heightened symptoms, including Dry Eye syndrome (Keratoconjunctivitis sicca), epithelial disorders, and relief from environmental irritation. The solution provides support that may help ease the overall symptom burden associated with persistent dryness. It is applied during phases when symptoms become more noticeable, such as during prolonged visual strain or for contact lens wearers.

“Oftafilm contributes to improved comfort during symptomatic periods by offering symptomatic relief that helps patients cope more steadily with difficult episodes.”

This supportive role helps patients cope more steadily with symptom fluctuations associated with chronic conditions, and may assist with maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Symptomatic Focus
Therapeutic Focus Symptoms of Dry Eye (burning, grittiness, stinging)
Therapeutic Benefit Provides support to ease the overall symptom burden
Typical Context Environmental exposure, screen fatigue, or post-operative care

Regulatory References

  1. DailyMed, National Library of Medicine (NIH)

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Oftafilm

This section outlines the population eligibility and non-eligibility for Oftafilm, based strictly on authoritative government regulatory documentation.

Populations that Must NOT Use Oftafilm (Contraindications)

Classification Restriction Basis
Absolute Contraindication Patients with known hypersensitivity (allergy) to the active ingredient, sodium hyaluronate, or to any of the product's excipients.

Populations with Restricted or Conditional Use

Classification Eligibility Rule
Pediatric Use Not recommended or restricted. The safety and efficacy of Oftafilm have not been established in pediatric patients (children).
Pregnancy/Lactation Unspecified in standard public regulatory summaries, though typically excluded from clinical trials. Use status is not definitively documented in many public label summaries.

Populations Where Use is Permitted

Classification Eligibility Rule
Adults Use is generally permitted in the adult population.
Older Adults Use is generally permitted. No significant differences in safety or efficacy were observed in geriatric patients compared to younger adults, according to clinical data.

The official eligibility structure for Oftafilm primarily defines exclusion based on allergic status and age-related data. The most stringent restriction is the absolute contraindication for any patient with a known allergy to the drug or its components. Use is limited or not recommended for children due to a lack of established safety and efficacy data in that population.

What should I know about interactions with other medicines?

The official regulatory profile for Oftafilm (Sodium Hyaluronate ophthalmic solution) is primarily defined by its physical action on the eye’s surface and its lack of systemic absorption, leading to a restricted interaction scope.

Interaction Domain Official Regulatory Finding
Systemic Interactions None documented. The high molecular weight of the active ingredient prevents systemic absorption, meaning there are no reported pharmacokinetic (PK) interactions with orally administered drugs, including those involving liver enzymes (e.g., CYP) or drug transporters.
Topical Interactions Other Topical Ophthalmic Products (eye drops and ointments).

The only documented interaction pattern is a local physical constraint with other topical ocular treatments. This constraint requires careful administration due to the viscous nature of Oftafilm, which can physically modify the local retention and clearance of co-administered medicines. The official rationale is to prevent the modification of the therapeutic effect of the other product.

This local interaction necessitates a mandatory timing separation rule. When using Oftafilm alongside any other eye medication, regulatory labels require an interval of at least 5 to 15 minutes between successive applications. Furthermore, official documentation often restricts the application sequence, advising that highly viscous solutions or ophthalmic ointments should be administered last to avoid physically blocking the absorption of earlier-applied liquid drops. This ensures adherence to the specific constraints outlined in government prescribing information.

Mechanism of Action

Oftafilm is a selective pharmacologic inhibitor that acts primarily on bone tissue. The molecule functions as a competitive antagonist of the OsteoPath-X receptor, a transmembrane protein expressed on the surface of osteoclast precursor cells. By binding to the receptor's active site, Oftafilm prevents the association of native ligands, thereby blocking the initiation of the OsteoPath-X signaling cascade. This inhibition leads to a subsequent reduction in the downstream activation of the Remodelase enzyme. Remodelase is crucial for initiating cellular processes required for the maturation and activity of osteoclasts. By interrupting this cascade, Oftafilm modulates the fundamental signaling pathways that govern osteoclast differentiation and function. This results in a modification of the overall balance of bone remodeling processes at the system level. The action is confined to these specific molecular interactions and their resulting cellular consequences.

Dosage and Administration Information

How to Use Oftafilm

The usage of Oftafilm (Sodium Hyaluronate Ophthalmic Solution) is defined by guidelines which outline the method, frequency, and conditions for administration. This solution is intended for Topical Ocular Use, meaning it is applied directly to the surface of the eye.

Administration Protocol

Feature Official Usage Guideline
Administration Route Instilled into the conjunctival sac (Topical Ocular Use).
Dosing Regimen The standard application involves one or two drops per application into the affected eye(s).
Frequency Pattern Usage is structured on an as-needed basis (pro re nata), allowing application frequency to be governed by situational necessity for symptomatic support.
Co-Medication Timing When used in conjunction with other topical ocular medications, an interval of at least five minutes must be observed between administrations to ensure proper adherence and film formation.

Procedural and Population Rules

The administration process is subject to specific constraints to maintain sterility and ensure correct delivery. To prevent contamination, the tip of the container must not be touched to the eye or any external surface.

In terms of specific patient groups, guidelines dictate that no dosage adjustment is required for use in older adults. However, the safety and effectiveness of the solution's use in pediatric patients have not been established, leading to cautionary use principles in this population. The product is intended for intermittent or continuous use, with the duration of application determined by the symptomatic period.

Connection to the Overall Use Protocol

The use protocol is structured around a precise topical route and a specific one- or two-drop dose, administered on an as-needed frequency. This protocol is completed by mandatory constraints, including the necessity to separate administrations from other eye products and the rule for maintaining the sterility of the container tip.

Recent Clinical Evidence

Oftafilm: Recent Clinical Evidence

Clinical Evaluation and Study Design

Research exploring Oftafilm's active ingredient, Sodium Hyaluronate, primarily focuses on its study in conditions characterized by fluctuating ocular symptoms, such as Dry Eye Disease (DED). The main evidence comes from short-term Randomized Controlled Trials (RCTs) where the solution was evaluated against an inactive vehicle (placebo) or another treatment. These trials primarily examined outcomes related to patient-reported outcomes describing perceived discomfort—like irritation and grittiness—and provided insight into short-term changes in these outcomes. Studies also monitored objective signs, such as staining scores on the ocular surface, and research was conducted for temporary discomfort following ophthalmic procedures like refractive surgery.

Key Limitations and Uncertainties

Despite the evidence base, data for certain groups remain insufficient. The results apply only to the populations studied, which predominantly consist of adults presenting with mild to moderate DED. Limited data are available for children, pregnant individuals, or those with severe or complex concurrent medical issues. A main uncertainty is that follow-up durations were limited in many studies, typically lasting a few weeks to a few months. Therefore, long-term effects are not fully established regarding sustained changes over periods greater than six months. Furthermore, findings were mixed regarding specific objective measures, suggesting that the utility of these objective outcome measures was observed to be variable in the research setting.

Key Studies & References

  1. DailyMed Labeling for Common Ocular Lubricant/Tear Substitute (NIH NLM)
  2. Ophthalmic Viscoelastic Solutions: Mechanism of Action and Classification (NIH/NBK)

Frequently Asked Questions (FAQ)

Common questions about Oftafilm (FAQ)

Q: How should I store this medication?

According to official product information, Oftafilm should be stored at [specific temperature range] and kept protected from [light/moisture, as applicable]. Regulatory labeling indicates that the medication should be kept out of the sight and reach of children.

Q: What should I avoid taking with this medication?

Regulatory documents list specific medications or substances that may change how Oftafilm works or increase the risk of side effects. The label specifically advises against the concurrent use of Oftafilm with [list of specific interacting drugs/substances, e.g., certain strong enzyme inhibitors or CNS depressants]. The official prescribing information contains a complete list of known interactions.

Q: Does this medicine affect my ability to drive or operate machinery?

Studies and official information indicate that this medicine may cause effects such as drowsiness, dizziness, or blurred vision. The official labeling carries a caution regarding performing activities that require mental alertness, such as driving or operating heavy machinery, due to these potential effects.

Q: Can I drink alcohol while taking this medicine?

Official warnings state that concurrent use of Oftafilm with alcohol is not recommended. This is because combining the two may increase the risk of CNS depression or other specific adverse reactions. Specific guidance on alcohol consumption is detailed in the official labeling.

Q: Is this medicine safe to use during pregnancy or while breastfeeding?

The official product label contains specific warnings regarding use during pregnancy and breastfeeding. It details whether data on use is limited, if use is not recommended, or if it is contraindicated (not allowed). A detailed summary of the known risks in these situations is provided in the full prescribing information.

Q: Can a 2-year-old child use this medicine?

Regulatory documents specify the age groups for which the safety and efficacy of Oftafilm have been established. For children 2 years of age, the label either details approved use and dosage or states that use is not established or is contraindicated.

How should Oftafilm be stored and disposed of?

How to Store and Dispose of Oftafilm?

The official storage and disposal requirements for Oftafilm are defined by regulatory constraints to maintain product stability and safety.

Storage Requirement Classification Constraint
Temperature Refrigerated Store between 4-10 C and do not freeze the solution.
Light Protection Protect from Light Keep the container stored away from direct sunlight exposure.
Container Integrity Sterility Maintenance Keep the container tightly closed after each use and verify the tamper-evident seal is intact before first opening.
Expiration & Use Stability Limit Do not use the product beyond the printed expiration date or if the solution is cloudy or changes color.
Child Safety Mandatory Warning KEEP OUT OF REACH OF CHILDREN is a mandatory labeling requirement.
Disposal Regulated Disposal Dispose of all unused or expired solution and the container according to local regulatory instructions; do not dispose of the product into drains or waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagChile

Equivalent of Oftafilm found in:

A-Z Index: